Update: Facial Filler Use Now Reported by Moderna COVID-19 Vaccine Trial Participants
Moderna mRNA-1273-P301 study participants will now be asked to disclose information about their use of facial fillers.
Participants in the Moderna mRNA-1273-P301 study received an information letter regarding an “important addition” to the eDairy that they keep. They were notified that as of February 22, 2021, volunteers in the COVID-19 vaccine trial will be asked 2 questions about the use of dermal fillers.
On February 10, 2021, the Centers for Disease Control and Prevention (CDC) issued interim clinical considerations for the use of mRNA COVID-19 vaccines that included a statement online pertaining to patients who have a history of dermal filler use as part of their Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States document, under the section entitled “Vaccination of persons with underlying medical conditions.”
Recently, we reported on the guidance the American Society of Dermatologic Surgery released including data from the United States Food and Drug Administration on reactions associated with the SARS-CoV-2) mRNA vaccine and dermal fillers.
Although the vaccine is supported as highly protective against the virus, shortly after its deployment, reports emerged of a few unexpected side effects in people who had a history of facial fillers.
Reference
Centers for Disease Control and Prevention. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. Updated February 10, 2021. Accessed February 26, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
